Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction

OBJECTIVE: To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8 years with specific focus on dosage and the duration of intervals between infliximab infusions. METHODS: EASIC included patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, X, Heldmann, F, van den Bosch, F, Burmester, G, Gaston, H, van der Horst-Bruinsma, I E, Krause, A, Schmidt, R, Schneider, M, Sieper, J, Andermann, B, van Tubergen, A, Witt, M, Braun, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964174/
https://www.ncbi.nlm.nih.gov/pubmed/27493791
http://dx.doi.org/10.1136/rmdopen-2016-000272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964174/
https://www.ncbi.nlm.nih.gov/pubmed/27493791
http://dx.doi.org/10.1136/rmdopen-2016-000272

Ejemplares similares